Arbutus Biopharma ( (ABUS) ) has issued an announcement.
Genevant Sciences and Arbutus Biopharma have initiated international patent infringement lawsuits against Moderna, targeting alleged unauthorized use of their LNP technology in Moderna’s products across 30 countries. The legal actions seek monetary relief and injunctions, expanding on ongoing proceedings in the U.S., and highlight the critical role of LNP technology in mRNA delivery, a field where both companies have significant expertise and investment.
More about Arbutus Biopharma
Genevant Sciences is a leading nucleic acid delivery company with a robust lipid nanoparticle (LNP) patent portfolio, specializing in RNA-based applications such as vaccines and gene editing. Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious diseases, particularly chronic hepatitis B, and is invested in LNP delivery technology through its partnership with Genevant.
YTD Price Performance: 4.86%
Average Trading Volume: 832,905
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $653.7M
For an in-depth examination of ABUS stock, go to TipRanks’ Stock Analysis page.